Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023

Boan Biotech's BA1202 Administered to First Subject

Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been administered to the first subject in a Phase I clinical trial. This makes BA1202 the first CEA/CD3 bispe...

Boan Biotech Announces 2023 Half Year Results

Boan Biotech (6955.HK) announced its 2023 half year results and recent developments on August 27, 2023.Highlights of 2023 half year resultsRobust revenue growthIn the first half of 2023, the company&r...

Announcement of Interim Results for the Six Months Ended 30 June 2023

Notice of Board Meeting

Articles of Association

Voluntary Announcement Amendments to the Articles of Association

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023